PATIENT DETAILS	*Affix patient Addressograph if available
SURNAME:	FIRST NAME(S):
DATE OF BIRTH://_	MRN:



NDMS Multiple Sclerosis Patient Eligibility Form Ublituximab (Briumvi®)

Form must be completed in full and saved securely in the patient's medical record for audit purposes only

TREATMENT	HSE APPROVED INDICATION	ICD10	Protocol
			Code
Ublituximab	Ublituximab (Briumvi) is indicated for the treatment of adult patients with	G35	MS104
(Briumvi [®])	relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features		

ELIGIBILITY	GIBILITY				NO		
Indication as per Protocol MS104							
Eligibility criteria in Protocol MS104 have	been satisfied						
EXCLUSIONS					NO		
All exclusion criteria laid out in protocol	MS104 have been cons	IS104 have been considered					
PREVIOUS MEDICATION(S) FOR MULTIPLE SCLEROSIS							
Name of Medicine (in order of use; 1. =	Reason for change in treatment (please tick)						
first line etc.)	Adverse Event	Loss of Response	Othe	er Reason			
1.							
2.							
3.							
4.							
5.							
PRESCRIBER DETAILS	PRESCRIBER DETAILS						
Prescriber Name							
Medical Registration Number							
ELIGIBILITY FORM COMPLETED BY							
Name							
Date							

Protocol: MS - Ublituximab	Published: November 2024 Review: November 2026	Version Number: 1
AIDMP Protocol Code: MS104	Contributor: Prof Christopher McGuigan as Multiple Sclerosis Lead for the National Clinical Programme for Neurology	Page 1 of 1

The information contained in this document is a statement of consensus from the National Clinical Programme for Neurology regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibly of the prescribing clinician. and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer